GCP
VTVT icon

GSA Capital Partners’s vTv Therapeutics VTVT Stock Holding History

GSA Capital Partners’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,887
Closed -$177K – 1836
2021
Q3 		$177K Buy
+2,887
New +$218K 0.02% 1261
2020
Q4 		– Sell
-958
Closed -$68K – 1636
2020
Q3 		$68K Buy
+958
New +$84.2K 0.01% 1164
2017
Q2 		– Sell
-824
Closed -$216K – 1979
2017
Q1 		$216K Buy
+824
New +$188K 0.01% 1535

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GSA Capital Partners's VTVT Position: Q4 2021 in Review

GSA Capital Partners sold out of vTv Therapeutics (VTVT) in Q4 2021, closing a stake of 2,887 shares — an estimated $177K sold.

GSA Capital Partners first reported a position in VTVT in Q1 2017 and held it in 3 quarters. The position peaked at $216K in Q1 2017. 29 funds tracked by Wall St. Rank hold VTVT as of Q4 2021.

  • GSA Capital Partners reported no remaining vTv Therapeutics position as of Q4 2021 after selling out during the quarter.
  • GSA Capital Partners sold 2,887 vTv Therapeutics shares in Q4 2021, an estimated $177K.
  • GSA Capital Partners first reported a position in vTv Therapeutics in Q1 2017 and held it in 3 quarters.
  • GSA Capital Partners's vTv Therapeutics position peaked at $216K in Q1 2017.
  • 29 funds tracked by Wall St. Rank held vTv Therapeutics as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.